FDA Enhances Transparency by Publishing Over 200 Rejection Letters to Drugmakers
The FDA has begun publishing over 200 complete response letters (CRLs) issued between 2020 and 2024 to increase transparency and provide the public with insights into its decision-making process regarding drug and biological product approvals, aiming to improve predictability and reduce repeated mistakes in drug development.